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A B S T R A C T
Objective: To describe the effects of high-frequency oscillatory ventilation (HFOV) as a 
rescue ventilatory support in pediatric patients with acute respiratory distress syndrome 
(ARDS). 
Methods: Twenty-five children (1 month < age < 17 years) admitted to a university hospital 
pediatric intensive care unit (ICU) with ARDS and submitted to HFOV for a minimum of 
48 hours after failure of conventional mechanical ventilation were assessed. 
Results: 28 days after the onset of ARDS, the mortality rate was 52% (13/25). Over the course 
of 48  hours, the use of HFOV reduced the oxygenation index [38 (31-50) vs. 17 (10  - 27)] 
and increased the ratio of partial arterial pressure O2 and fraction of inspired O2 [65 [44-80) 
vs. 152 (106-213)]. Arterial CO2 partial pressure [54 (45-74) vs. 48 (39-58) mmHg] remained 
unchanged. The mean airway pressure ranged between 23  and 29  cmH2O. HFOV did not 
compromise hemodynamics, and a reduction in heart rate was observed (141 ± 32 vs. 119 ± 22 
beats/min), whereas mean arterial pressure (66 ± 20 vs. 71 ± 17 mmHg) and inotropic score 
[44 (17-130) vs. 20 (16-75)] remained stable during this period. No survivors were dependent 
on oxygen. 
Conclusion: HFOV improves oxygenation in pediatric patients with ARDS and severe 
hypoxemia refractory to conventional ventilatory support.
© 2012 Elsevier Editora Ltda. 
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Ventilação oscilatória de alta frequência em crianças com síndrome 
da angústia respiratória aguda: experiência de um centro de tratamento 
intensivo pediátrico
R E S U M O
Objetivo: Descrever os efeitos da aplicação da ventilação de alta frequência oscilatória como 
suporte ventilatório de resgate em uma série de pacientes pediátricos com síndrome da 
angústia respiratória aguda (SARA).
Métodos: Participaram do estudo 25 crianças (> 1 mês e < 17 anos) internadas em uma UTI 
pediátrica universitária com SARA e submetidas à ventilação de alta frequência oscilatória 
(VAFO) por um mínimo de 48 horas, após falha da ventilação mecânica convencional.
Resultados: A taxa de mortalidade foi de 52% (13/25) 28  dias após o início da SARA. Ao 
longo de 48  horas, a aplicação da VAFO reduziu o índice de oxigenação [38 (31-50) vs. 17 
(10-27)] e aumentou a relação pressão arterial parcial de O2/fração inspirada de O2  [65 
(44-80) vs. 152 (106-213)]. A pressão arterial parcial de CO2 [54 (45-74) vs. 48 (39-58) mmHg] 
manteve-se inalterada. A pressão média de vias aéreas oscilou entre 23 e 29 cmH2O. A VAFO 
não comprometeu a hemodinâmica e observou-se uma redução da frequência cardíaca 
(141 ±  32  vs. 119  ±  22  bat/min), a pressão arterial média (66 ±  20  vs. 71 ±  17  mmHg) e o 
escore inotrópico [44 (17-130) vs. 20 (16-75)] mantiveram-se estáveis nesse período. Nenhum 
sobrevivente ficou dependente de oxigênio. 
Conclusão: VAFO melhora a oxigenação de pacientes pediátricos com SARA grave e hipoxemia 
refratária ao suporte ventilatório convencional.
Palavras-chave:
Síndrome da angústia respiratória 
 aguda
Ventilação de alta frequência 
 oscilatória
Insuficiência respiratória
Pediatria
Ventilação mecânica protetora
Introduction
The prevalence of acute respiratory distress syndrome (ARDS) 
in pediatric intensive care units varies from 2% to 7.6%.1,2 In 
pediatrics, ARDS is associated with high mortality rates, which 
vary according to the service, population studied, and risk 
factors. Clinical studies suggest that mechanical ventilation 
(MV) may modify inflammatory responses in patients with 
acute lung injury. In patients with prior pulmonary and 
systemic inflammation, ventilation with tidal volumes (VT) of 
10-15 mL/kg of ideal body weight (IBW) and moderate-to-low 
levels of positive end-expiratory pressure (PEEP) are associated 
with increased levels of intra-alveolar and systemic 
inflammatory mediators.3 In contrast, mechanical ventilation 
with moderate-to-high levels of PEEP and reduced VT of 
approximately 6 mL/kg of IBW ensured proper gas exchange, 
reduced systemic and intra-alveolar inflammatory mediators, 
and decreased mortality.3-6
The use of protective ventilatory strategies that 
prevent further lung injury associated with MV is a major 
concern in any patient, including those without acute 
pathology.7 High-frequency oscillatory ventilation (HFOV) 
is a protective ventilatory strategy, as it optimizes alveolar 
recruitment and lung volume, as well as improves oxygenation 
by applying high-flow rates and frequencies up to 900 cycles 
per minute with reduced tidal volumes (1-2 mL/kg) resulting 
from minor differences in inspiratory and expiratory pressures, 
producing a high and persistent mean airway pressure.8
HFOV appears to represent an important therapeutic option 
in ventilatory support of children with respiratory failure. 
Despite the increased use of HFOV in pediatric patients with 
acute respiratory failure, there have been few published studies, 
as well as few prospective studies and randomized clinical trials 
involving children with ARDS.9-12 HFOV has been more often 
used as a rescue therapy in children with severe respiratory 
failure after failure of conventional mechanical ventilation 
(CMV) with lung protective strategies.12-15 However, to date 
there is insufficient evidence to support its use.16,17 When HFOV 
is shown to be effective as a rescue therapy, this ventilation 
mode will become an extremely useful therapeutic option.18,19
The present study aimed to describe the effects of the use 
of HFOV as a rescue ventilatory support over oxygenation and 
ventilation in pediatric patients diagnosed with ARDS. 
Methods
Study design
This was an observational and retrospective study performed 
through the analysis of medical records of children admitted 
between 2005 and 2010 with ARDS,20 submitted to HFOV due 
to treatment failure with conventional mechanical ventilation.
Patient selection 
The study was performed at the pediatric ICU of the Hospital 
da Criança Santo Antônio, which has 30 beds in a university 
hospital complex. The study was approved by the Ethics 
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Committee of the Complexo Hospitalar Santa Casa de Porto 
Alegre (registration No.: 1935/08).
Patients were considered eligible for the study according to 
the following criteria: a) 1 month < age < 17 years, b) used HFOV 
for ARDS management (chest X-ray with bilateral infiltrates, 
ratio of partial pressure of arterial oxygen and inspired oxygen 
fraction [PaO2/FiO2] ≤ 200, and no clinical evidence of left atrial 
hypertension); c) failed protective conventional mechanical 
ventilation (CMV) (children: peak inspiratory pressure 
[PIP] > 35 cmH2O, mean airway pressure [MAwP] > 15-18 cmH2O 
and FiO2 ≥ 0.6; term infants: MAwP ≥ 10-12 cm H2O, FiO2 ≥ 0.6, 
and failure to increase lung volume); and d) complete medical 
records. The decision to switch to HFOV considering the 
difficulty to maintain ventilatory parameters/oxygenation was 
made by the attending physician.
Patients were excluded from the study if HFOV was applied 
for less than 48 hours in the event of death or early weaning 
from HFOV in the same period.
Data were collected on diagnosis (primary and associated) 
and outcome variables (time in HFOV, time in CMV before and 
after HFOV, duration of ICU stay, in-hospital mortality, and 
mortality at day 28 after the ARDS diagnosis).
Ventilatory strategies 
Conventional mechanical ventilation
Initially, all patients used pressure-controlled CMV (Servo 
300, Siemens-Elema AB –Sweden; SERVOi, Maquet GmbH 
& Co, KG – Rastatt, Germany). The ventilation strategy 
consisted of “protective ventilation” with FiO2 < 0.5, tolerating 
a saturation of arterial hemoglobin oxygen (SaO2) > 85%, 
permissive hypercapnia as long as pH >  7.2, and a tidal 
volume < 7 mL/kg of ideal body weight. The ventilation mode 
used was synchronized intermittent mandatory ventilation 
with controlled pressure and assisted pressure. The general 
support included sedation (continuous infusion of opioid and 
benzodiazepine), fluid maintenance, nutritional support, and 
antibiotics when indicated. Whenever necessary, a muscle 
relaxant (pancuronium) was used to facilitate mechanical 
ventilation. Hemodynamic support with vasopressors/inotropes 
and/or fluids was administered through a central venous 
catheter when necessary. 
High-frequency oscillatory ventilation
All patients submitted to HFOV were ventilated with a 
High-Frequency Oscillator Sensor Medics 3100B (Sensor 
Medics – Yorba Linda, CA, USA). Until the year 2007, there 
was no protocol for the start of HFOV, and HFOV parameters 
were chosen at the discretion of the attending physician. 
From 2008 onward, the following protocol was adopted: 
MAwP  =  5  cmH2O above the MAwP in CMV, FiO2  =  1.0, 
amplitude adjusted to achieve adequate power for chest wall 
vibration, and airflow maintained at 30 mL/min. The initial 
oscillatory frequency was adjusted between 10-15 Hz. To attain 
HFOV weaning, FiO2 was kept between 0.4 and 0.6, followed 
by a decrease of 1 to 2 cmH2O to decrease airway pressure. 
Regarding ventilation, there were progressive reductions 
(3-5 cmH2O) in amplitude pressure. CMV would be resumed 
when airway pressure was ≤ 20 cmH2O, FiO2 ≤ 0.4, and when 
the patient tolerated the aspiration of the endotracheal tube 
without oxygen saturation decrease.21,22
Monitoring
Arterial blood gases and ventilatory parameters were collected 
in CMV (peak inspiratory pressure [PIP], positive pressure 
at the end of exhalation, positive end-expiratory pressure 
[PEEP], respiratory rate [RR], fraction of inspired oxygen [FiO2], 
inspiratory time) at the beginning of HFOV use and after 6, 12, 
24, and 48 hours (mean airway pressure [MAwP], amplitude 
[AMP], RR, FIO2). The oxygenation index (OI = [MAwP X FIO2 X 
100]/PaO2)
23 and the PaO2/FiO2 ratio were calculated in the 
same time intervals. Hemodynamic parameters (heart rate 
[HR] and mean arterial pressure [MAP]) and inotropic score 
(dopamine X 10 +  adrenaline X 100) were obtained over 
48 hours.24 Patient severity was evaluated through the Pediatric 
Index of Mortality (PIM) score.25
Statistical analysis 
Analysis of variance and Student’s t-test were used to 
analyze the data with normal distribution (Tukey’s test for 
comparisons). The nonparametric Mann-Whitney test and 
Friedman’s ANOVA (Dunn test for comparisons) were used for 
variables with non-normal distribution. Results were expressed 
as mean ± standard deviation or median (25-75 percentile). 
Results
Patient characteristics
Table 1 describes patient characteristics and mortality rates. 
There were 31 identified patients who were diagnosed with 
ARDS, submitted to HFOV during a five-year period. Six patients 
were excluded; five died within less than 24 hours, and one was 
weaned from HFOV before 48 hours, leaving 25 patients at the 
final analysis. The patients had high risk of death with high 
mortality rate and aggressive ventilatory support before the use 
of HFOV. The associated comorbidities were: postoperative of 
congenital surgery (n = 6), Cushing’s syndrome (n = 1), anoxic 
encephalopathy (n = 3), hematologic malignancies (n = 3), major 
burn injury (n = 1), late complications of kidney transplantation 
(n = 1), cytomegalovirus (n = 1), pulmonary lymphangioma (n = 1), 
postoperative of late kidney transplantation (n = 1), prematurity 
(n = 3), neonatal anoxia (n = 1), hyaline membrane disease (n = 1), 
bronchopulmonary dysplasia (n = 1), postoperative of pulmonary 
surgery (n = 2), and nonspecific immune deficiency (n = 1).
Ventilation and oxygenation parameters
After 48 hours of HFOV, FiO2 decrease and a significant increase 
in SaO2 were achieved. The effect of HFOV on patients’ 
significant ventilatory improvement was verified by reducing 
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the oxygenation index and increasing the PaO2/FiO2 ratio 
(Fig. 1) over 48 hours. PaCO2 remained almost unchanged. The 
MAwP necessary to maintain oxygenation with progressive 
reduction of FiO2 during the 48 hours of HFOV ranged between 
23 and 29 cmH2O. 
Hemodynamic parameters 
Before HFOV use, 20  patients were receiving one or a 
combination of vasoactive drugs; 24 hours after the start of 
HFOV, three other patients needed a drug or combination 
of vasoactive drugs (dopamine, n = 22; noradrenaline, n = 6; 
adrenaline, n = 10; milrinone, n = 3). The two main causes 
of hemodynamic instability were septic shock (n = 17) and 
postoperative of heart surgery. Only two patients did not 
need vasoactive drugs. Even with high mean airway pressures, 
hemodynamic performance was not impaired by HFOV; it 
was also observed that HR decreased significantly and MAP 
remained stable. Moreover, the inotropic score remained 
unchanged during the evaluation period.
In seven patients with bronchiolitis, the PaO2/FiO2 ratio 
increased from 62 ± 25 to 193 ± 114 (p = 0.027), and OI decreased 
from 48 ± 17 to 15 ± 7 (p = 0.001) over 48 hours. Furthermore, 
the PaCO2 decreased (59 ± 17 vs. 42 ± 10 mmHg, p = NS) during 
this same period. 
Clinical outcomes 
Table 1 shows the main clinical outcomes. The improvement 
of the parameters related to oxygenation was higher in 
survivors than in non-survivors (Table 2). No survivors were 
dependent on oxygen. Among the complications potentially 
related to ventilation and/or pulmonary disease, ten patients 
had nonhypertensive pneumothorax without additional 
hemodynamic involvement.
Comparison between the pre-protocol and post-protocol periods 
of high-frequency oscillatory ventilation implementation 
Table 3 describes the comparison of the main physiological 
and clinical outcomes for the two periods. No significant 
differences were observed among the seven patients who were 
ventilated without an adjuvant protocol and the remaining 
18 patients who were ventilated based on the established HFOV 
protocol since 2008. 
Discussion
The present study, which involved a sample of patients with 
severe ARDS submitted to rescue HFOV, did not allow for 
the determination of the true effectiveness of this method. 
However, the results indicate that HFOV significantly improves 
gas exchange and allows reductions in oxygen supply. These 
findings are consistent with other studies that evaluated the 
use of HFOV in pediatric patients with ARDS, and suggest 
that the benefit would be greater with an earlier start of 
Variables n = 25
Age (months) 9 (4-81)
Weight (kg) 7 (4-19)
Gender (M/F) 13/12
PIM 30 ± 24
Mortality rate 28 days after ARDS 52% (13/25)
Time in ICU (days) 19 (13-37)
Time of HFOV (h) 82 (72-144)
Time in ICU pre-death (days) 17 (12-37)
Time of CMV pre-HFOV (hours) 24 (19-144)
Time of CMV post-HFOV (hours) 72 (0-276)
PIP (mmHg) 37 ± 6
PEEP (cmH2O) 11 ± 4
RR (resp/min) 34 ± 9
FiO2 0.95 ± 0.13
Diagnosis
 Pneumonia 9
 Pneumonia (RSV+) 1
 Bronchiolitis (RSV+) 5
 Bronchiolitis 2
 Extra-pulmonary ARDS 6
ARDS, acute respiratory distress syndrome; CMV, conventional 
mechanical ventilation; F, female; FiO2, fraction of inspired 
oxygen; ICU, intensive care unit; HFOV, high-frequency oscillatory 
ventilation; M, male; PEEP, positive end-expiratory pressure; 
PIM, pediatric index of mortality; PIP, peak inspiratory pressure; 
RR, respiratory rate; RSV, respiratory syncytial virus.
Data are shown as median (25-75 percentiles) or mean ± standard 
deviation.
Each patient may have had more than one diagnosis.
Table 1 – Patient characteristics, respiratory failure 
severity, and clinical outcomes.
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Figure 1 – Changes in oxygenation index and arterial partial 
pressure of oxygen/fraction of inspired oxygen during the 
initial 48 hours of high-frequency oscillatory ventilation 
(HFOV). HFOV was established at time 0, which represents 
the values immediately before the HFOV. Values are 
expressed as median with 25-75% percentiles. ap < 0.001 
(Friedman’s ANOVA); bp < 0.05, compared to the previous 
level (Tukey’s test). 
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HFOV, especially in the first 24 hours in cases associated with 
refractory hypoxemia.10,16,26 Even though the median time of 
CMV before HFOV was around 24 hours in this study, it must be 
concluded that the indication was delayed. It can be observed 
that at the moment of transition, a mean FiO2 of 95% was used 
in CMV, as well as a mean PIP of 37 mmHg, thus maintaining 
a high shunt fraction (refractory hypoxemia). Therefore, the 
use of HFOV should not be based on time of evolution, but on 
refractoriness to CMV.
The decision to indicate HFOV defined by a criterion 
of refractory response to CMV is reinforced by another 
observation from the present study. There were no differences 
between patients submitted to HFOV with no defined protocol 
(up to 2007) when compared with those in whom HFOV was 
used according to clear definitions of utilization. Patients did 
not differ in severity or ventilatory parameters at the beginning 
of HFOV implementation, and had the same clinical outcome. 
It can be speculated that the definition of decision criteria for 
changing the ventilatory method is more important than HFOV 
implementation using a strict protocol.
HFOV, even when started late, promoted significant 
improvement in OI and PaO2/FiO2 ratio during the 48 hours. 
Most studies have indicated HFOV as a rescue ventilatory 
support for ARDS patients who had difficulties in CMV with 
worsening of OI.10,12,17 A survey among 14 centers, which 
included 232 pediatric patients, demonstrated a mean OI 
of 27 before HFOV.12 In the present study, when HFOV was 
indicated, the mean OI was almost 40, confirming that the 
decision to perform the transition was probably late for most 
cases. Several studies have focused on OI as a predictor of 
mortality after the transition to HFOV.12,16 Sarnaik et al. 
suggested that, in patients with initial OI < 20, the absence 
of a decrease of at least 20% in OI within the first six hours of 
HFOV may be considered a predictor of death.15
Classically, HFOV uses relatively high MAwP, allowing 
for a more effective maintenance of lung recruitment than 
that promoted by the use of PEEP in CMV.22,27 In the present 
study MAwP increased significantly after start of HFOV, with 
significant improvement in oxygenation indices, suggesting 
the opening of a major portion of alveolar units with improved 
gas exchange (alveolar recruitment). The impact on PaCO2 was 
not significant due to adjustments in the amplitude of the 
respirator, in order to prevent unnecessary and unwanted 
alveolar hyperventilation.9,16,17,28
With the increase in MAwP during HFOV, hemodynamic 
impairment can occur, as pleural pressure elevation 
Variablesa 0 h 6 h 12 h 24 h 48 h p valueb
PaO2, mmHg 64 (46-77) 70 (55-98) 75 (61-96) 73 (48-98) 74 (56-96) 0.749
FiO2  0.95 ± 0.13 – – – 0.55 ± 0.22 < 0.001
SatO2, % 86±10 86 ± 20 93 ± 8* 92 ± 11 91 ± 13 0.001
PaCO2, mmHg 54 (45-74) 54 (36-72) 52 (39-65) 40 (34-58) 48 (39-58) 0.620
MAwP, cmH2O 23.7 ± 3.4 29.2 ± 4.0
b 29.0 ± 3.8  27 ± 4.5 25.5 ± 5.5 < 0.001
HR, beats/min 141 ± 32 140 ± 15 133 ± 20 126 ± 20 119 ± 22* 0.002
Temp, oC 36.4 ± 1.4 36.2 ± 0.8 36.2 ± 0.7 36.0 ± 0.9 35.6 ± 0.9 0.068
MAP, mmHg 66 ± 20 65 ± 16 72 ± 19 72 ± 15 71 ± 17 0.149
Inotropic score 44 (17-30) 45 (30-110) 35 (16-58) 22 (15-74) 20 (16-75) 0.243
FiO2, fraction of inspired oxygen; HR, heart rate; MAP, mean arterial pressure; MAwP, mean airway pressure; PaO2, arterial partial pressure of 
oxygen; PaCO2, partial pressure of arterial carbon dioxide, SatO2, arterial oxygen saturation; Temp, temperature.
aDescribed by median (percentiles 25-75) or mean ± SD. Analysis of variance (ANOVA) or Friedman’s test.
bp < 0.05 comparatively to the previous level (Tukey’s or Dunn’s test).
Table 2 – Alterations in blood gas, oxygenation, and hemodynamic variables within the first 48 hours. 
Variablesa  0 h 6 h 12 h 24 h 48 h
PaO2, mmHg NS 56 (46-73) 67 (42-86) 66 (48-79) 65 (43-90) 59 (52-76)
S 65 (47-77) 74 (61-115) 92 (77-109) 78 (62-108) 88 (71-118)
PaO2/FiO2 NS 56 (42-73) 69 (56-138) 109 (75-151)
b 123 (75-145) 112 (82-139)
S 67 (47-88) 94 (73-171) 116 (92-175) 145 (123-271)b 197 (161-267)a
OI NS 41 (36-59) 39 (24-59) 27 (22-46) 22 (13-42) 17 (14-35)
S 35 (27-44) 34 (13-42) 28 (13-33) 19 (10-25) 13 (7-21)
PaCO2, mmHg NS 48 (43-63) 55 (38-67) 44 (36-66) 39 (34-51) 47 (44-52)
 S 63 (48-76) 54 (31-76) 59 (42-69) 45 (34-68) 44 (37-52)
FiO2, fraction of inspired oxygen; OI, oxygenation index; PaO2, arterial partial pressure of oxygen; PaCO2, partial pressure of arterial carbon 
dioxide.
ap < 0.005 comparatively to the previous level (Dunn’s test). 
bp = 0.004 between groups.
Table 3 – Changes in blood gas and oxygenation variables within the first 48 hours for non-survivors (NS, n = 13) 
and survivors (S, n = 12) after 28 days of acute respiratory distress syndrome. 
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causes a decrease in venous return and cardiac output. 
Most patients in the present study were already receiving 
inotropic-vasoactive drugs during CMV; the use of HFOV did 
not impair hemodynamic stability and there was a decrease 
in hemodynamic support throughout the 48 hours. A study 
by Mehta et al. in adult patients showed that HFOV can 
lead to increased filling pressures and significant decrease 
in cardiac output.29  In contrast, Derdak et al. found no 
significant differences in heart rate, mean arterial pressure, 
or cardiac output between adult patients undergoing HFOV 
versus those submitted to CMV within the first 72 hours of 
treatment.30 Although cardiac output was not measured in 
the present study, the observed hemodynamic performance 
suggests that there was no additional blood flow impairment 
in the present patients, as MAP remained stable and HR 
decreased. 
The mortality from ARDS in children has been decreasing 
to around 20%.31-33  Although some researchers have 
estimated that it is higher,34 with explicit protocols in certain 
populations of children with ARDS, mortality can be as low 
as 8%.35 However, ARDS patients continue to be among those 
at higher risk in pediatric ICUs, with prolonged mechanical 
ventilation time and increased risk for nosocomial infections, 
as well as increased risk for unknown respiratory morbidities 
and neurodevelopmental injuries. In the present study, a 
mortality rate of 52% after 28 days of ARDS diagnosis and 
treatment with HFOV was observed. When evaluating the high 
mortality rate from ARDS observed in this group, it should 
be noted that: a) this was a selected group of patients with 
refractory hypoxemia in CMV (mean PIP of 30 and FIO2 = 95%), 
b) a large number of patients presented septic shock and 
several co-morbidities, c) there was sample selection, which 
excluded from the study those patients in whom HFOV was 
used for less than 48 hours (milder cases), and d) there was 
a lack of an explicit protocol for conventional ventilatory 
support and transition to HFOV. It is known that the initial 
severity of the oxygenation defect, non-pulmonary organ 
failure, and the presence of neurological dysfunction are 
independent predictors of mortality in children with ARDS.31 In 
studies of populations with similar severity, severe sepsis and 
multiple-organ failure are common causes of death in patients 
with ARDS, with a mortality rate that can reach 61%.36
The rate of pneumothorax after HFOV initiation was 
particularly high. However, no patient developed chronic 
lung disease, and no survivors remained more than 28 days 
on oxygen therapy. In the study by Arnold et al., the incidence 
of barotrauma was lower (25%), but the need for prolonged 
supplemental oxygen was of 21%.10 
One of the contraindications related to HFOV is in 
patients with increased airway resistance, such as asthma 
and bronchiolitis.21 Seven patients with bronchiolitis were 
ventilated through HFOV, of which three survived. Oxygenation 
improved significantly in these patients and there was a trend 
toward improved ventilation. The present results are similar 
to those obtained by Berner et al., who also demonstrated 
lower oxygen supplementation and improvement of other 
gas exchange parameters.37 However, at the time of HFOV 
implementation, as the patients met the criteria for ARDS, 
it is possible that the benefit may have been observed on 
alveolar-interstitial alterations, characteristic of ARDS, and 
not on small airway obstruction, characteristic of bronchiolitis. 
This study has certain limitations related to its retrospective 
design, the data from medical records that were sometimes 
incomplete, and the size and heterogeneity of the studied 
population sample. In addition, the study was performed in 
a single center; these limitations, when considered together, 
make any extrapolation of results uncertain. 
Conclusion
In patients with severe ARDS and severe hypoxemia refractory 
to conventional ventilatory support, HFOV promotes sustained 
improvement in oxygenation indices. 
However, randomized controlled trials are still needed to 
identify whether HFOV can become an alternative ventilatory 
method to conventional ventilation modes, and to establish 
the optimal time for its use.
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